Current GU Protocols for Prostate Cancer

RTOG 0232-A Phase III Study of Comparing Combined External Beam Radiation & Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostate Carcinoma

Principal Investigator- Dr. John Fiveash
- Lisa Clemons/Research Nurse (975-2880)

This study evaluates the use of radiation seed implants (Brachytherapy) in combination with External Beam radiation as treatment for patients with intermediate risk prostate cancer.

UAB 9921-A Randomized PhaseIIb Clinical Trial of DFMO vs. CASODEX in Patients with Prostate Cancer in the period prior to Radical Prostatectomy or Brachytherapy

Principal Investigator- Dr. Donald Urban (975-0088)

Patients diagnosed with prostate cancer and who select either surgery or internal radiation (Brachytherapy) as treatment will be randomly selected to take either Casodex or DFMO to evaluate Polyamine biomarkers. Polyamine biomarkers are indicators of prostate cancer, and the study will evaluate the use of Casodex or DFMO as chemo-preventative agents to reduce the risk of prostate cancer.

**This study is closed to active patient accrual, but subsequent follow-up studies may follow, utilizing similar study parameters.

UAB 0359-A Phase II Trial of Doxil with or without Dexamethasone in treatment of Patients with Metastatic Hormone Refractory Prostate Cancer.

Principal Investigator- Dr. Graeme Bolger (934-2992)

This clinical trial is for men with an advanced stage prostate cancer who have failed regular hormone regimen for prostate cancer. The trial involves a visit to the Hematology Clinic to receive treatments once a week for three weeks to evaluate control of prostate cancer by utilizing the PSA score.

RAD 0003-Factors Predictive of Urinary Retention after Prostate Brachytherapy

Principal Investigator- Dr. John Fiveash (934-5670)

This study evaluates the urinary symptoms of patients undergoing internal radiation therapy (Brachytherapy). Patients will have a uroflow measure, post-void residual test, and completion of an AUA symptom score sheet to evaluate urinary symptoms prior to treatment, and again at one month and six month intervals. The purpose of the study is to evaluate how Brachytherapy affects urinary control in men with prostate cancer.

RTOG 9902- Androgen Suppression and Radiation Therapy plus Chemotherapy for Patients with Localized, High Risk Prostate Cancer

Principal Investigator- Dr. Ruby Meredith (934-5670)

This study is for patients who have biopsy confirmed prostate cancer. Patients however, are high risk for prostate cancer recurrence as determined by their PSA, tumor stage and Gleason score. Patients will receive Androgen Suppression medications for eight weeks and then undergo radiation therapy for up to eight weeks. Patients will then have additional AS meds for 20 months after radiation therapy.

RAD 0103- In Vivo 3D Dosimetry for radiotherapy Patients undergoing High Dose Rate Brachytherapy

Principal Investigator- Dr. John Fiveash Lisa Clemons/Research Nurse (975-2880)

The study evaluates the use of high dose radiation therapy combined with patients undergoing I-125 radiation seed implants for localized prostate cancer.

UAB 0212 - A clinical trial Evaluating the Safety and Efficacy of ABX-EGF in Patients with Hormone Resistant Prostate Cancer with Elevated PSA without Metastasis

Principal Investigator - Andres Forero, MD (975-2837)

ABX/EGF is a promising monoclonal antibody targeting the antigen Epidermal Growth Factor Receptor. They should have three consecutive elevated PSAs and have tumor tissue available for pathology evaluation. All patients will receive the antibody once weekly for eight weeks. The antibody has been used in colon cancer with excellent tolerance and minimal toxicity.